Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 301–400 of 1,017
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210
An analysis of genetic heterogeneity in untreated cancers
Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0185-x · Cited by 209
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
Self-citationGeffen, Y., Anand, S., Akiyama, Y., Yaron, T. M., Song, Y., Johnson, J. L., Govindan, A., Babur, Ö., Li, Y., Huntsman, E., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.013 · Cited by 209
Self-citationGibson, W. J., Hoivik, E. A., Halle, M. K., Taylor-Weiner, A., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 206
Self-citationLer, L. D., Ghosh, S., Chai, X., Thike, A. A., Heng, H. L., Siew, E. Y., Dey, S., Koh, L. K., Lim, J. Q., Lim, W. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8312 · Cited by 208
Autophagy in cancer development, immune evasion, and drug resistance
Niu, X., You, Q., Hou, K., Tian, Y., Wei, P., Zhu, Y., Gao, B., Ashrafizadeh, M., Aref, A. R., Kalbasi, A., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101170 · Cited by 191
Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5689 · Cited by 206
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
“…short DNA strands from randomly fragmented copies of a genome (Meyerson et al. 2010; Mardis 2011), and its use in genome (Patel et al. 2013), exome (Lawrence et al. 2014), epigenome (Lee et al. 2013), transcriptome (Martens-Uzunova et al. 2013), and other sequencing analyses may provide novel…”
Cancer: Evolution Within a Lifetime
Gerlinger, M., McGranahan, N., Dewhurst, S. M., Burrell, R. A., Tomlinson, I., & Swanton, C. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092314 · Cited by 205
Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 206
GTP-Dependent K-Ras Dimerization
Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202
“K-Ras, which is frequently mutated in human cancer (Lawrence et al., 2014), is the most potent activator of Raf among Ras isoforms (Prior et al., 2012).”
BackgroundComprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers
Wang, Z.-L., Li, B., Luo, Y.-X., Lin, Q., Liu, S.-R., Zhang, X.-Q., Zhou, H., Yang, J.-H., & Qu, L.-H. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.035 · Cited by 204
CDK7 inhibitors as anticancer drugs
Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L., & Ali, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09885-8 · Cited by 200
Genomic–transcriptomic evolution in lung cancer and metastasis
Martínez-Ruiz, C., Black, J. R. M., Puttick, C., Hill, M. S., Demeulemeester, J., Larose Cadieux, E., Thol, K., Jones, T. P., Veeriah, S., Naceur-Lombardelli, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05706-4 · Cited by 201
Higher‐order oligomerization promotes localization of SPOP to liquid nuclear speckles
Marzahn, M. R., Marada, S., Lee, J., Nourse, A., Kenrick, S., Zhao, H., Ben‐Nissan, G., Kolaitis, R., Peters, J. L., Pounds, S., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593169 · Cited by 202
“Recent efforts to sequence the cancer genome have identified many mutations in SPOP that are associated with cancers (Lawrence et al , 2014), notably prostate (Kim et al , 2013), breast (Kim et al , 2011), endometrial (Le Gallo et al , 2012), and gastric (Kim et al , 2013) cancers [Appendix Fig S1…”
Centrosomes and cancer: revisiting a long-standing relationship
Gönczy, P. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3995 · Cited by 201
Malyutina, A., Majumder, M. M., Wang, W., Pessia, A., Heckman, C. A., & Tang, J. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006752 · Cited by 197
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier
Santos, M. A., Faryabi, R. B., Ergen, A. V., Day, A. M., Malhowski, A., Canela, A., Onozawa, M., Lee, J.-E., Callen, E., Gutierrez-Martinez, P., et al. (2014) · Nature · doi:10.1038/nature13483 · Cited by 196
Multiomic Analysis of the UV-Induced DNA Damage Response
Boeing, S., Williamson, L., Encheva, V., Gori, I., Saunders, R. E., Instrell, R., Aygün, O., Rodriguez-Martinez, M., Weems, J. C., Kelly, G. P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.047 · Cited by 198
Saladi, S. V., Ross, K., Karaayvaz, M., Tata, P. R., Mou, H., Rajagopal, J., Ramaswamy, S., & Ellisen, L. W. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.001 · Cited by 197
“In addition, other subunit genes of the SWI/SNF complex including ARID1A (BAF250) are mutated frequently in certain carcinomas (Lawrence et al., 2014).”
BackgroundPrecision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
Castro-Vega, L. J., Letouzé, E., Burnichon, N., Buffet, A., Disderot, P.-H., Khalifa, E., Loriot, C., Elarouci, N., Morin, A., Menara, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7044 · Cited by 196
“Importantly, we did not find any recurrent mutations in PCCs/PGLs, but it is expected that analysis of more samples could help identify significant genes of low mutation frequency 34 .”
Differential Stoichiometry among Core Ribosomal Proteins
Slavov, N., Semrau, S., Airoldi, E., Budnik, B., & van Oudenaarden, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.056 · Cited by 195
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Liu, F., Hon, G. C., Villa, G. R., Turner, K. M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A. Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.002 · Cited by 193
“GBM is one of the most deeply ecular Cell 60, 307–318, October 15, 2015 ª2015 Elsevier Inc. 315 genomically characterized forms of cancer (Lawrence et al., 2014), revealinga remarkably highprevalenceofEGFRamplification and mutations (Brennan et al., 2013), even at the single cell level (Patel et…”
Variation in genomic landscape of clear cell renal cell carcinoma across Europe
Scelo, G., Riazalhosseini, Y., Greger, L., Letourneau, L., Gonzàlez-Porta, M., Wozniak, M. B., Bourgey, M., Harnden, P., Egevad, L., Jackson, S. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6135 · Cited by 193
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Self-citationUnni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q., & Varmus, H. (2015) · eLife · doi:10.7554/elife.06907 · Cited by 190
“…genes; the point in the evolution of a tumor when a mutation occurs (since that will affect the percentage of cells containing the mutant allele); and the selective advantage or disadvantage of the mutation for the growth and survival of the cell in which it occurred (Lawrence et al., 2013, 2014).”
BackgroundOmori, Y., Ono, Y., Tanino, M., Karasaki, H., Yamaguchi, H., Furukawa, T., Enomoto, K., Ueda, J., Sumi, A., Katayama, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.029 · Cited by 190
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Zhu, K., Wu, Y., He, P., Fan, Y., Zhong, X., Zheng, H., & Luo, T. (2022) · Cells · doi:10.3390/cells11162508 · Cited by 190
Carlevaro-Fita, J., Lanzós, A., Feuerbach, L., Hong, C., Mas-Ponte, D., Pedersen, J. S., PCAWG Drivers and Functional Interpretation Group, Abascal, F., Amin, S. B., Bader, G. D., et al. (2020) · Communications Biology · doi:10.1038/s42003-019-0741-7 · Cited by 187
Self-citationTargeting histone lysine methylation in cancer
McGrath, J., & Trojer, P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.002 · Cited by 186
Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours
Litchfield, K., Summersgill, B., Yost, S., Sultana, R., Labreche, K., Dudakia, D., Renwick, A., Seal, S., Al-Saadi, R., Broderick, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6973 · Cited by 187
Targeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
Role of ribosomal protein mutations in tumor development (Review)
GOUDARZI, K. M., & LINDSTRÖM, M. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3387 · Cited by 185
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C. M., Van Gulick, R., Kazakoff, S. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18988-3 · Cited by 186
Expanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 185
“Recent methods have shown that combining different signals of positive selection holds great potential for finding reliable lists of driver genes 103 .”
MethodBalmus, G., Pilger, D., Coates, J., Demir, M., Sczaniecka-Clift, M., Barros, A. C., Woods, M., Fu, B., Yang, F., Chen, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07729-2 · Cited by 184
Modeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 183
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W.-T., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W.-L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 184
CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer
Kemp, C. J., Moore, J. M., Moser, R., Bernard, B., Teater, M., Smith, L. E., Rabaia, N. A., Gurley, K. E., Guinney, J., Busch, S. E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.004 · Cited by 182
PI3K inhibitors: review and new strategies
Zhang, M., Jang, H., & Nussinov, R. (2020) · Chemical Science · doi:10.1039/d0sc01676d · Cited by 178
Sosinsky, A., Ambrose, J., Cross, W., Turnbull, C., Henderson, S., Jones, L., Hamblin, A., Arumugam, P., Chan, G., Chubb, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02682-0 · Cited by 179
“https://doi.org/10.1038/s41591-023-02682-0 with previous reports 18 , we found that skin cutaneous melanoma and lung adenocarcinoma had the highest average TMB (Fig.”
BackgroundInfluentialGenomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Van Allen, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 179
ESCO1 and CTCF enable formation of long chromatin loops by protecting cohesinSTAG1 from WAPL
Wutz, G., Ladurner, R., St Hilaire, B. G., Stocsits, R. R., Nagasaka, K., Pignard, B., Sanborn, A., Tang, W., Várnai, C., Ivanov, M. P., et al. (2020) · eLife · doi:10.7554/elife.52091 · Cited by 178
“They may also be of relevance for understanding the aetiology of human cancers, in which STAG2 expression is often lost (Lawrence et al., 2014; Leiserson et al., 2015; Solomon et al., 2011).”
BackgroundMolecular Analysis for Therapy Choice: NCI MATCH
Conley, B. A., & Doroshow, J. H. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.05.002 · Cited by 179
Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y., Liu, X., Lim, C. H., Koh, T. P. T., Aung, Z. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02584-z · Cited by 173
POSTAR: a platform for exploring post-transcriptional regulation coordinated by RNA-binding proteins
Hu, B., Yang, Y.-C. T., Huang, Y., Zhu, Y., & Lu, Z. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw888 · Cited by 174
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Bakouny, Z., Braun, D. A., Shukla, S. A., Pan, W., Gao, X., Hou, Y., Flaifel, A., Tang, S., Bosma-Moody, A., He, M. X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21068-9 · Cited by 174
Park, J., Yang, J., Wenzel, A. T., Ramachandran, A., Lee, W. J., Daniels, J. C., Kim, J., Martinez-Escala, E., Amankulor, N., Pro, B., et al. (2017) · Blood · doi:10.1182/blood-2017-02-768234 · Cited by 172
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
The genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident
Morton, L. M., Karyadi, D. M., Stewart, C., Bogdanova, T. I., Dawson, E. T., Steinberg, M. K., Dai, J., Hartley, S. W., Schonfeld, S. J., Sampson, J. N., et al. (2021) · Science · doi:10.1126/science.abg2538 · Cited by 169
Self-citationAn update of Nrf2 activators and inhibitors in cancer prevention/promotion
Pouremamali, F., Pouremamali, A., Dadashpour, M., Soozangar, N., & Jeddi, F. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00906-3 · Cited by 171
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0160 · Cited by 169
Self-citationGenomic evolution and chemoresistance in germ-cell tumours
Taylor-Weiner, A., Zack, T., O’Donnell, E., Guerriero, J. L., Bernard, B., Reddy, A., Han, G. C., AlDubayan, S., Amin-Mansour, A., Schumacher, S. E., et al. (2016) · Nature · doi:10.1038/nature20596 · Cited by 170
Self-citationCanisius, S., Martens, J. W. M., & Wessels, L. F. A. (2016) · Genome Biology · doi:10.1186/s13059-016-1114-x · Cited by 169
P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Lara, R., Adinolfi, E., Harwood, C. A., Philpott, M., Barden, J. A., Di Virgilio, F., & McNulty, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00793 · Cited by 169
Mouhieddine, T. H., Sperling, A. S., Redd, R., Park, J., Leventhal, M., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 167
Self-citationTranslating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer
Tran, N., Broun, A., & Ge, K. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00341-20 · Cited by 168
Epigenetics of hematopoiesis and hematological malignancies
Hu, D., & Shilatifard, A. (2016) · Genes & Development · doi:10.1101/gad.284109.116 · Cited by 168
“Indeed, high-throughput, genome-scale sequencing has revealed that chromatinmodifiers are among themost frequently mutated in cancer in general, particularly in he- matological malignancies, suggesting prominent roles played by the epigenetic alterations in these diseases (Lawrence et al. 2014).”
BackgroundDevelopment and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Speers, C., Zhao, S., Liu, M., Bartelink, H., Pierce, L. J., & Feng, F. Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2898 · Cited by 167
Enhancer Logic and Mechanics in Development and Disease
Rickels, R., & Shilatifard, A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.003 · Cited by 166
Rho GTPases in cancer: friend or foe?
Svensmark, J. H., & Brakebusch, C. (2019) · Oncogene · doi:10.1038/s41388-019-0963-7 · Cited by 165
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini Rocco, E., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020) · Genes · doi:10.3390/genes11070719 · Cited by 166
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, E. J., Braun, M.-G., Heald, R. A., MacLeod, C., Chan, C., Clausen, S., Edgar, K. A., Eigenbrot, C., Elliott, R., Endres, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01422 · Cited by 158
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Ng, C. K. Y., Piscuoglio, S., Geyer, F. C., Burke, K. A., Pareja, F., Eberle, C. A., Lim, R. S., Natrajan, R., Riaz, N., Mariani, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2857 · Cited by 165
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
Australian Ovarian Cancer Study Group, Ryland, G. L., Hunter, S. M., Doyle, M. A., Caramia, F., Li, J., Rowley, S. M., Christie, M., Allan, P. E., Stephens, A. N., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0210-y · Cited by 164
Prioritizing targets for precision cancer medicine
Andre, F., Mardis, E., Salm, M., Soria, J.-C., Siu, L. L., & Swanton, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu478 · Cited by 164
Thandapani, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.014 · Cited by 163
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer
Sze, C. C., & Shilatifard, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026427 · Cited by 164
“Interestingly, one such subunit, ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX), has also been documented to be frequently mutated in cancer (Kandoth et al. 2013; Lawrence et al. 2014).”
BackgroundRecurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Wagner, A. H., Devarakonda, S., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 163
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06303-1 · Cited by 158
Self-citationModelling bladder cancer in mice: opportunities and challenges
Kobayashi, T., Owczarek, T. B., McKiernan, J. M., & Abate-Shen, C. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3858 · Cited by 160
The cancer COMPASS: navigating the functions of MLL complexes in cancer
Ford, D. J., & Dingwall, A. K. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.005 · Cited by 162
SETD2: an epigenetic modifier with tumor suppressor functionality
Li, J., Duns, G., Westers, H., Sijmons, R., van den Berg, A., & Kok, K. (2016) · Oncotarget · doi:10.18632/oncotarget.9368 · Cited by 162
A step-by-step microRNA guide to cancer development and metastasis
Markopoulos, G. S., Roupakia, E., Tokamani, M., Chavdoula, E., Hatziapostolou, M., Polytarchou, C., Marcu, K. B., Papavassiliou, A. G., Sandaltzopoulos, R., & Kolettas, E. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0341-9 · Cited by 161
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Kumar, S., Warrell, J., Li, S., McGillivray, P. D., Meyerson, W., Salichos, L., Harmanci, A., Martinez-Fundichely, A., Chan, C. W. Y., Nielsen, M. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.032 · Cited by 160
Self-citationExperimental evolution reveals hidden diversity in evolutionary pathways
Lind, P. A., Farr, A. D., & Rainey, P. B. (2015) · eLife · doi:10.7554/elife.07074 · Cited by 161
“In the context of cancer, the mutational heterogeneity of different cancer types is well documented and it is possible that the common (and less common) mutational trajectories (Yates and Campbell, 2012; Lawrence et al., 2014) make sense in light of constraints due to genetic architecture.”
BackgroundMammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
St. Pierre, R., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 159
MUFFINN: cancer gene discovery via network analysis of somatic mutation data
Cho, A., Shim, J. E., Kim, E., Supek, F., Lehner, B., & Lee, I. (2016) · Genome Biology · doi:10.1186/s13059-016-0989-x · Cited by 160
“To obtain sufficient statistical power to detect cancer driver genes with low mutation frequency, a very large population of cancer patients would have to be sequenced [19].”
BackgroundPhenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants
Brenan, L., Andreev, A., Cohen, O., Pantel, S., Kamburov, A., Cacchiarelli, D., Persky, N. S., Zhu, C., Bagul, M., Goetz, E. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.061 · Cited by 160
“As a result, tumorassociated mutations have been detected in nearly all human genes and the number of uncharacterized mutations continues to rise (Lawrence et al., 2014).”
InfluentialSelf-citationMulti-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
HEPAVAC Consortium, Löffler, M. W., Mohr, C., Bichmann, L., Freudenmann, L. K., Walzer, M., Schroeder, C. M., Trautwein, N., Hilke, F. J., Zinser, R. S., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0636-8 · Cited by 160
Lapek, J. D., Greninger, P., Morris, R., Amzallag, A., Pruteanu-Malinici, I., Benes, C. H., & Haas, W. (2017) · Nature Biotechnology · doi:10.1038/nbt.3955 · Cited by 158
Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer
Yen, T.-T., Wang, T.-L., Fader, A. N., Shih, I.-M., & Gaillard, S. (2020) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000585 · Cited by 158
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
Wang, C., Gu, Y., Zhang, K., Xie, K., Zhu, M., Dai, N., Jiang, Y., Guo, X., Liu, M., Dai, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10499 · Cited by 158
Early and multiple origins of metastatic lineages within primary tumors
Zhao, Z.-M., Zhao, B., Bai, Y., Iamarino, A., Gaffney, S. G., Schlessinger, J., Lifton, R. P., Rimm, D. L., & Townsend, J. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525677113 · Cited by 158
A disordered region controls cBAF activity via condensation and partner recruitment
Patil, A., Strom, A. R., Paulo, J. A., Collings, C. K., Ruff, K. M., Shinn, M. K., Sankar, A., Cervantes, K. S., Wauer, T., St. Laurent, J. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.032 · Cited by 157
Tug-of-war between driver and passenger mutations in cancer and other adaptive processes
McFarland, C. D., Mirny, L. A., & Korolev, K. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404341111 · Cited by 156
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Horak, P., Fröhling, S., & Glimm, H. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000094 · Cited by 179
PD-L1 expression testing in non-small cell lung cancer
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763493 · Cited by 156
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
Genomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 167
Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions
Ji, X., Dadon, D. B., Abraham, B. J., Lee, T. I., Jaenisch, R., Bradner, J. E., & Young, R. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502971112 · Cited by 155
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Knisbacher, B. A., Lin, Z., Hahn, C. K., Nadeu, F., Duran-Ferrer, M., Stevenson, K. E., Tausch, E., Delgado, J., Barbera-Mourelle, A., Taylor-Weiner, A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01140-w · Cited by 154
Self-citationAndrysik, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154
“To test these ideas, we analyzed genomic data for 4429 samples from 19 different cancer types available through The Cancer Genome Atlas (TCGA, http:// cancergenome.nih.gov/) (Lawrence et al. 2014).”
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.